Yang Wenlu, Chen Xinyun, Cohen David S, Rosin Eric R, Toga Arthur W, Thompson Paul M, Huang Xudong
Department of Electrical Engineering, Information Engineering College, Shanghai Maritime University, Shanghai, China.
Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Int J Clin Exp Med. 2017 Dec;10(12):16004-16026.
Alzheimer's disease (AD) is a progressive, and often fatal, brain disease that causes neurodegeneration, resulting in memory loss as well as other cognitive and behavioral problems. Here, we propose a novel multimodal method combining independent components from MRI measures and clinical assessments to distinguish Alzheimer's patients or mild cognitive impairment (MCI) subjects from healthy elderly controls. 70 AD subjects (mean age: 77.15 ± 6.2 years), 98 MCI subjects (mean age: 76.91 ± 5.7 years), and 150 HC subjects (mean age: 75.69 ± 3.8 years) were analyzed. Our method includes the following steps: pre-processing, estimating the number of independent components from the MR image data, extracting effective voxels for classification, and classification using a support vector machine (SVM)-based classifier. As a result, with regards to classifying AD from healthy controls, we achieved a classification accuracy of 97.7%, sensitivity of 99.2%, and specificity of 96.7%; for differentiating MCI from healthy controls, we achieved a classification accuracy of 87.8%, a sensitivity of 86.0%, and a specificity of 89.6; these results are better than those obtained with clinical measurements alone (accuracy of 79.5%, sensitivity of 74.0%, and specificity of 85.1%). We found that (1) both AD patients and MCI subjects showed brain tissue loss, but the volumes of gray matter loss in MCI subjects was far less, supporting the notion that MCI is a prodromal stage of AD; and (2) combining gray matter features from MRI and three commonly used measures of mental status, cognitive function improved classification accuracy, sensitivity, and specificity compared with classification using only independent components or clinical measurements.
阿尔茨海默病(AD)是一种进行性且通常致命的脑部疾病,会导致神经退行性变,进而引起记忆丧失以及其他认知和行为问题。在此,我们提出一种新颖的多模态方法,该方法结合了MRI测量的独立成分和临床评估,以区分阿尔茨海默病患者或轻度认知障碍(MCI)受试者与健康老年对照。对70名AD受试者(平均年龄:77.15±6.2岁)、98名MCI受试者(平均年龄:76.91±5.7岁)和150名健康对照受试者(平均年龄:75.69±3.8岁)进行了分析。我们的方法包括以下步骤:预处理、从MR图像数据估计独立成分的数量、提取用于分类的有效体素,以及使用基于支持向量机(SVM)的分类器进行分类。结果,在将AD与健康对照进行分类方面,我们实现了97.7%的分类准确率、99.2%的灵敏度和96.7%的特异性;在将MCI与健康对照进行区分方面,我们实现了87.8%的分类准确率、86.0%的灵敏度和89.6%的特异性;这些结果优于仅通过临床测量获得的结果(准确率79.5%、灵敏度74.0%和特异性85.1%)。我们发现:(1)AD患者和MCI受试者均表现出脑组织损失,但MCI受试者的灰质损失量要少得多,这支持了MCI是AD前驱期的观点;(2)与仅使用独立成分或临床测量进行分类相比,将MRI的灰质特征与三种常用的精神状态测量方法相结合可提高分类准确率、灵敏度和特异性。